Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for rapid symptom relief in Early-Stage muscle disease

NCT ID NCT06909214

Disease control Sponsor: argenx Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called efgartigimod in 30 adults who were diagnosed with generalized myasthenia gravis (gMG) within the past year. The goal is to see if it can quickly reduce muscle weakness and daily-life symptoms. Participants receive weekly injections for about a year, and researchers track how many achieve minimal or no symptoms within the first 16 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Is at least 18 years when signing the ICF * Has been diagnosed with gMG of MGFA class II, III, or IV * Is seropositive for AChR-Ab * Is treatment-naive for gMG or has been administered AChEI for the treatment of gMG * Had onset of generalized MG signs and/or symptoms within 12 months before screening; candidates who also had onset of ocular MG signs and/or symptoms within 24 months before screening may be enrolled in the study * Has an MG-ADL score ≥5 Exclusion Criteria: * gMG diagnosis of MGFA class I or V * Underwent a thymectomy prior to screening, except thymectomy for treatment of nonmalignant thymoma prior to the gMG diagnosis * Prior or current use of any of any systemic corticosteroid therapy or nonsteroidal immunosuppressive therapy for the treatment of gMG

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for New onset generalized myasthenia gravis (GMG) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

New onset generalized myasthenia gravis (GMG)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    18 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Baycare Medical Group

    RECRUITING

    St. Petersburg, Florida, 33705, United States

    Contact Email: •••••@•••••

  • Center for Neurological Disorders - Greenfield

    RECRUITING

    Greenfield, Wisconsin, 53228-1321, United States

    Contact Email: •••••@•••••

  • Central Texas Neurology Consultants - Elligo

    RECRUITING

    Round Rock, Texas, 78681, United States

    Contact Email: •••••@•••••

  • Cleveland Clinic

    RECRUITING

    Cleveland, Ohio, 44195, United States

    Contact Email: •••••@•••••

  • EZR Research

    RECRUITING

    Boca Raton, Florida, 33486, United States

    Contact Email: •••••@•••••

  • Emory Brain Health Center

    RECRUITING

    Atlanta, Georgia, 30329, United States

    Contact Email: •••••@•••••

  • Erlanger Neuroscience Institute

    RECRUITING

    Chattanooga, Tennessee, 37403, United States

    Contact Email: •••••@•••••

  • HSHS Medical Group

    RECRUITING

    O'Fallon, Illinois, 62269, United States

    Contact Email: •••••@•••••

  • Hawaii Pacific Neuroscience

    RECRUITING

    Honolulu, Hawaii, 96817, United States

    Contact Email: •••••@•••••

  • Henry Ford Health System

    RECRUITING

    Detroit, Michigan, 48202, United States

    Contact Email: •••••@•••••

  • Medsol Clinical Research Center Inc

    RECRUITING

    Port Charlotte, Florida, 33952, United States

    Contact Email: •••••@•••••

  • Samir Macwan, M.D., Inc. (S corporation)

    RECRUITING

    Rancho Mirage, California, 92270, United States

    Contact Email: •••••@•••••

  • The Queen's Medical Center - West Oahu

    RECRUITING

    Honolulu, Hawaii, 96813, United States

    Contact Email: •••••@•••••

  • UMass Memorial Medical Center

    RECRUITING

    Worcester, Massachusetts, 01655, United States

    Contact Email: •••••@•••••

  • University of California Irvine

    RECRUITING

    Orange, Florida, 92868, United States

    Contact Email: •••••@•••••

  • University of California, San Diego - Altman Clinical and Translational Research Institute (ACTRI)

    RECRUITING

    La Jolla, California, 92037, United States

    Contact Email: •••••@•••••

  • University of Florida Jacksonville

    RECRUITING

    Jacksonville, Florida, 32209, United States

    Contact Email: •••••@•••••

  • Visionary Investigators Network

    RECRUITING

    Miami, Florida, 33133, United States

    Contact Email: •••••@•••••